Emcure Pharmaceuticals announced that it has received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India (DCGI) for launching Molnupiravir to treat mild COVID-19. The company plans to launch the oral drug under the brand name Lizuvira in the Indian market, the company said in a statement.
As the need for such a drug is imminent in the face of emerging challenges in COVID- 19 treatment, the company will endeavour to deliver Lizuvira in a week’s time. A toll-free helpline will be dedicated to help the doctors and patients access the product.
Earlier this year, Emcure Pharma had entered into a licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low- and middle-income countries (LMICs).